

JosÃ© Luis Izquierdo Alonso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2400620/publications.pdf>

Version: 2024-02-01

58
papers

3,420
citations

172457

29
h-index

138484

58
g-index

71
all docs

71
docs citations

71
times ranked

3170
citing authors

#	ARTICLE	IF	CITATIONS
1	Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. <i>Lancet, The</i> , 2009, 374, 695-703.	13.7	557
2	Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC. <i>Archivos De Bronconeumologia</i> , 2012, 48, 331-337.	0.8	192
3	Short-term and Long-term Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis. <i>Chest</i> , 2004, 125, 953-964.	0.8	189
4	Consensus Document on the Overlap Phenotype COPDâ€“Asthma in COPD. <i>Archivos De Bronconeumologia</i> , 2012, 48, 331-337.	0.8	176
5	Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1746-1754.	3.2	166
6	The impact of COVID-19 on patients with asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003142.	6.7	164
7	GuÃ­a clÃ­nica SEPAR-ALAT de diagnÃ³stico y tratamiento de la EPOC. <i>Archivos De Bronconeumologia</i> , 2008, 44, 271-281.	0.8	143
8	Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. <i>Respiratory Medicine</i> , 2015, 109, 785-802.	2.9	108
9	Defective Natural Killer and Phagocytic Activities in Chronic Obstructive Pulmonary Disease Are Restored by Glycophosphopeptical (ImmunoferÃ³n). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1578-1583.	5.6	100
10	Comparison of roflumilast, an oral antiâ€“inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 72-78.	5.7	99
11	Clinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processing. <i>Journal of Medical Internet Research</i> , 2020, 22, e21801.	4.3	97
12	Efficacy and safety of roflumilast in the treatment of asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 679-686.	1.0	82
13	Extent of centrilobular and panacinar emphysema in smokers' lungs: pathological and mechanical implications. <i>European Respiratory Journal</i> , 1994, 7, 664-671.	6.7	70
14	Airway dysfunction in patients with Parkinson's disease. <i>Lung</i> , 1994, 172, 47-55.	3.3	69
15	Th-2 signature in chronic airway diseases: towards the extinction of asthmaâ€“COPD overlap syndrome?. <i>European Respiratory Journal</i> , 2017, 49, 1602397.	6.7	55
16	Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case–control study (CONSISTE study). <i>International Journal of COPD</i> , 2012, 7, 679.	2.3	52
17	Characteristics and Prognosis of COVID-19 in Patients with COPD. <i>Journal of Clinical Medicine</i> , 2020, 9, 3259.	2.4	51
18	Impact of COPD severity on physical disability and daily living activities: EDIP-EPOC I and EDIP-EPOC II studies. <i>International Journal of Clinical Practice</i> , 2009, 63, 742-750.	1.7	50

#	ARTICLE	IF	CITATIONS
19	Economic Impact of Pulmonary Drugs on Direct Costs of Stable Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 215-223.	1.6	46
20	Mixed Th2 and non-Th2 inflammatory pattern in the asthma–COPD overlap: a network approach. International Journal of COPD, 2018, Volume 13, 591-601.	2.3	44
21	Study of the burden on patients with chronic obstructive pulmonary disease. International Journal of Clinical Practice, 2009, 63, 87-97.	1.7	42
22	Fiabilidad del diagn&ostico de la EPOC en atenci&3n primaria y neumolog&Aa en Espa&±a. Factores predictivos. Archivos De Bronconeumologia, 2003, 39, 203-208.	0.8	42
23	Misdiagnosis of patients receiving inhaled therapies in primary care. International Journal of COPD, 2010, 5, 241.	2.3	40
24	Manejo cl&3nico de la EPOC en situaci&3n de vida real. An&3lisis a partir de big data. Archivos De Bronconeumologia, 2021, 57, 94-100.	0.8	38
25	What pulmonologists think about the asthma–COPD overlap syndrome. International Journal of COPD, 2015, 10, 1321.	2.3	35
26	Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors. International Journal of COPD, 2014, 9, 1053.	2.3	34
27	The dose of inhaled corticosteroids in patients with COPD: when less is better. International Journal of COPD, 2018, Volume 13, 3539-3547.	2.3	34
28	Tratamiento farmacol&3gico de la EPOC en dos niveles asistenciales. Grado de adecuaci&3n a las normativas recomendadas. Archivos De Bronconeumologia, 2003, 39, 195-202.	0.8	31
29	Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. Science Progress, 2022, 105, 003685042210745.	1.9	29
30	Asthma-COPD overlap is not a homogeneous disorder: further supporting data. Respiratory Research, 2017, 18, 183.	3.6	28
31	Findings and Prognostic Value of Lung Ultrasound in <sc>COVID</sc>–19 Pneumonia. Journal of Ultrasound in Medicine, 2021, 40, 1315-1324.	1.7	26
32	The variability of respiratory symptoms and associated factors in COPD. Respiratory Medicine, 2017, 129, 165-172.	2.9	24
33	Clinical Audit of Patients Admitted to Hospital in Spain due to Exacerbation of COPD (AUDIPOC Study): Method and Organisation. Archivos De Bronconeumologia, 2010, 46, 349-357.	0.8	23
34	The Role of Vitamin D in Chronic Obstructive Pulmonary Disease, Asthma and Other Respiratory Diseases. Archivos De Bronconeumologia, 2014, 50, 179-184.	0.8	22
35	Caracter&3sticas de los pacientes con EPOC tratados en neumolog&Aa en Espa&±a seg&3n grupos GOLD y fenotipos cl&3nicos GesEPOC. Archivos De Bronconeumologia, 2018, 54, 559-567.	0.8	22
36	Lack of association of ischemic heart disease with COPD when taking into account classical cardiovascular risk factors. International Journal of COPD, 2010, 5, 387.	2.3	19

#	ARTICLE	IF	CITATIONS
37	Papel de la vitamina D en enfermedad pulmonar obstructiva crónica, asma y otras enfermedades respiratorias. Archivos De Bronconeumología, 2014, 50, 179-184.	0.8	19
38	Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. International Journal of COPD, 2016, 11, 289.	2.3	17
39	Paciente exacerbador con enfermedad pulmonar obstructiva crónica: recomendaciones en procesos diagnósticos, terapéuticos y asistenciales. Archivos De Bronconeumología, 2019, 55, 478-487.	0.8	16
40	Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective. International Journal of COPD, 2020, Volume 15, 1621-1632.	2.3	13
41	Defining the Heterogeneity of Sleep Apnea Syndrome: A Cluster Analysis With Implications for Patient Management. Archivos De Bronconeumología, 2022, 58, 125-134.	0.8	12
42	Utility of Transfer Factor to Detect Different Bronchodilator Responses in Patients with Chronic Obstructive Pulmonary Disease. Respiration, 1998, 65, 282-288.	2.6	11
43	¿Cuál debe ser el papel del neumólogo en el tratamiento quimioterápico del cáncer de pulmón?. Archivos De Bronconeumología, 2003, 39, 483-484.	0.8	10
44	Utilización excesiva de corticoides inhalados en la enfermedad pulmonar obstructiva crónica. Archivos De Bronconeumología, 2012, 48, 207-212.	0.8	9
45	The Use of the Lower Limit of Normal as a Criterion for COPD Excludes Patients With Increased Morbidity and High Consumption of Health-Care Resources. Archivos De Bronconeumología, 2012, 48, 223-228.	0.8	8
46	Utilidad clínica e impacto económico de la punción transbronquial convencional de adenopatías mediastínicas en el carcinoma broncogénico. Archivos De Bronconeumología, 2013, 49, 41-46.	0.8	7
47	Comorbilidades de la enfermedad pulmonar obstructiva crónica. Archivos De Bronconeumología, 2016, 52, 547-548.	0.8	5
48	Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain. International Journal of COPD, 2022, Volume 17, 245-258.	2.3	5
49	Valoración de la EPOC: regreso al futuro. Archivos De Bronconeumología, 2010, 46, 53-55.	0.8	3
50	Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes. Archivos De Bronconeumología, 2018, 54, 559-567.	0.8	3
51	Diferencias entre GesEPOC y GOLD. Archivos De Bronconeumología, 2016, 52, 453-454.	0.8	2
52	Futuro de los marcadores biológicos en la EPOC. Archivos De Bronconeumología, 2017, 53, 541-542.	0.8	2
53	The Length of Time Healthy Subjects and Patients with Chronic Obstructive Pulmonary Disease Are Able to Withstand Maximal Inspiratory Pressure. Respiration, 1991, 58, 301-303.	2.6	1
54	Authors' Reply to: Minimizing Selection and Classification Biases Comment on "Clinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processing". Journal of Medical Internet Research, 2021, 23, e29405.	4.3	1

#	ARTICLE	IF	CITATIONS
55	Looking at the Heart of Patients with Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2015, 90, 187-188.	2.6	0
56	Cátedras de Patrocinio. Qué y para qué. <i>Revista De Investigación Y Educación En Ciencias De La Salud (RIECS)</i> , 2021, 6, 69-74.	0.0	0
57	The algae names and collection of the Spanish Phycologist Pedro González Guerrero. <i>Anales Del Jardín Botánico De Madrid</i> , 2017, 74, 047.	0.4	0
58	The 7 Cardinal Sins of COPD in Spain. <i>Archivos De Bronconeumologia</i> , 2022, 58, 498-503.	0.8	0